Back to search

Peptide record

TPDB08864

Antibacterial Hemolysis Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB08864
Antibacterial Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Hemolysis, and Toxicity) peptide sequence curated from AntiBP3, Peptipedia, HemoPI, and other sources, with an available 3D structural model.
Sequence
FLFKLIPKAIKKLISKFK
Physicochemical Analysis
C110H184N24O20
RNDCEQGHMTWYV
K
2162.82
11.21
6
0
10
+6
0.35
0.517
135.56
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
3
I
3
L
6
K
0
M
3
F
1
P
1
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 3 L: 3 K: 6 M: 0 F: 3 P: 1 S: 1 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
18
C110H184N24O20
2162.82
11.21
+6
0.35
0.517
Evidence Records 18 records
Evidence 1 Activity

Activity

94.8± 8.2% Cell death
Toxicity
256 µg/mL
Cytotoxic
94.8± 8.2% Cell death | 256 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 2 Activity

Activity

50% Cell death
Toxicity
101.4 µg/mL
Cytotoxic
50% Cell death | 101.4 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Evidence 3 Activity

Activity

10% Hemolysis
Toxicity
53 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 53 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 4 Activity

Activity

50% Hemolysis
Toxicity
256 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 5 Activity

Activity

0% Hemolysis
Toxicity
5 µM
Hemolytic Cytotoxic
0% Hemolysis | 5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. | Pharmaceuticals (Basel) | 2014
Evidence 6 Activity

Activity

1% Hemolysis
Toxicity
10 µM
Hemolytic Cytotoxic
1% Hemolysis | 10 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. | Pharmaceuticals (Basel) | 2014
Evidence 7 Activity

Activity

7% Hemolysis
Toxicity
20 µM
Hemolytic Cytotoxic
7% Hemolysis | 20 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. | Pharmaceuticals (Basel) | 2014
Evidence 8 Activity

Activity

17% Hemolysis
Toxicity
40 µM
Hemolytic Cytotoxic
17% Hemolysis | 40 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. | Pharmaceuticals (Basel) | 2014
Evidence 9 Activity

Activity

21% Hemolysis
Toxicity
60 µM
Hemolytic Cytotoxic
21% Hemolysis | 60 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. | Pharmaceuticals (Basel) | 2014
Evidence 10 Activity

Activity

29% Hemolysis
Toxicity
80 µM
Hemolytic Cytotoxic
29% Hemolysis | 80 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. | Pharmaceuticals (Basel) | 2014
Evidence 11 Activity

Activity

38% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
38% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. | Pharmaceuticals (Basel) | 2014
Evidence 12 Activity

Activity

50% Cell death
Toxicity
60-80 µM
Cytotoxic
50% Cell death | 60-80 | µM | target cell: Vero cells

Target

Vero cells

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. | Pharmaceuticals (Basel) | 2014
Evidence 13 Activity

Activity

50% Cell death
Toxicity
40 µM
Cytotoxic
50% Cell death | 40 | µM | target cell: Human embryonic kidney HEK293 cells

Target

Human embryonic kidney HEK293 cells

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Activity of AamAP1-Lysine, a Novel Synthetic Peptide Analog Derived from the Scorpion Venom Peptide AamAP1. | Pharmaceuticals (Basel) | 2014
Evidence 14 Activity

Activity

10% Hemolysis
Toxicity
94 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 94 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 15 Activity

Activity

50% Hemolysis
Toxicity
>256 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >256 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 16 Activity

Activity

99.1± 8.7% Cell death
Toxicity
256 µg/mL
Cytotoxic
99.1± 8.7% Cell death | 256 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 17 Activity

Activity

50% Cell death
Toxicity
124.4 µg/mL
Cytotoxic
50% Cell death | 124.4 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 18 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis